INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular Dystrophy
25 janv. 2023 07h45 HE
|
INmune Bio, Inc.
Boca Raton, Florida, Jan. 25, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the...
Univest Client INmune Bio, Inc. ("INMB”) to Ring NASDAQ Closing Bell
09 avr. 2019 13h28 HE
|
Univest Securities, LLC
New York, April 09, 2019 (GLOBE NEWSWIRE) -- Univest Securities client INmune Bio, Inc. (INmune Bio) (NASDAQ: INMB), a clinical stage immunology biotech company developing therapies in patients’...
INmune Bio Co-Founders to Present at World Immunotherapy Congress during the Festival of Biologics San Diego
26 févr. 2019 09h30 HE
|
INmune Bio, Inc.
Presentations to address the role of the innate immune system in treating cancer LA JOLLA, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused...
INmune Bio Awarded a $1 Million Grant for the Development of XPro1595 for the treatment of Alzheimer’s Disease
11 févr. 2019 08h00 HE
|
INmune Bio, Inc.
The Alzheimer’s Association awarded INmune Bio the Part the Cloud to RESCUE grant to target neuroinflammation in Alzheimer’s Disease LA JOLLA, Calif., Feb. 11, 2019 (GLOBE NEWSWIRE) -- INmune...
INmune Bio to Present at BIO CEO & Investor Conference
06 févr. 2019 09h00 HE
|
INmune Bio, Inc.
LA JOLLA, CA, Feb. 06, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (Nasdaq: INMB) (“INmune” or the “Company”), an immunotherapy company focused on developing therapies that harness the patient’s...
INmune Bio Inc. Announces Closing of Initial Public Offering and Trading on the Nasdaq Capital Market Under the Ticker Symbol “INMB”
04 févr. 2019 08h55 HE
|
INmune Bio, Inc.
LA JOLLA, CA, Feb. 04, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (“INmune” or the “Company”), an immunotherapy company focused on developing therapies that harness the patient’s innate immune system...